VXA-G1.1-NN

BIOLOGICAL6 trials

Sponsors

Vaxart

Conditions

Norovirus InfectionNorovirus Infections

Phase 1

Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines

CompletedNCT03897309

VaxartNorovirus Infection

Start: 2019-03-20End: 2021-04-01Updated: 2022-09-21

Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines

CompletedNCT04875676

VaxartNorovirus Infections

Start: 2021-04-30End: 2022-02-16Updated: 2024-05-22

Norovirus Challenge Study

CompletedNCT05212168

VaxartNorovirus Infections

Start: 2021-12-27End: 2023-10-27Updated: 2025-11-05

A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers

CompletedNCT05213728

VaxartNorovirus Infections

Start: 2022-01-24End: 2022-02-24Updated: 2024-06-21

A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old

CompletedNCT06944717

VaxartNorovirus Infections

Start: 2025-03-03End: 2026-04-14Updated: 2026-07-27

A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females and Their Nursing Infants

CompletedNCT07254728

VaxartNorovirus Infections

Start: 2023-10-27End: 2024-12-13Updated: 2026-04-15